Success Metrics

Clinical Success Rate
80.1%

Based on 145 completed trials

Completion Rate
80%(145/181)
Active Trials
7(3%)
Results Posted
46%(67 trials)
Terminated
36(17%)

Phase Distribution

Ph not_applicable
2
1%
Ph phase_2
124
60%
Ph phase_3
21
10%
Ph early_phase_1
1
0%
Ph phase_4
6
3%
Ph phase_1
53
25%

Phase Distribution

54

Early Stage

124

Mid Stage

27

Late Stage

Phase Distribution207 total trials
Early Phase 1First-in-human
1(0.5%)
Phase 1Safety & dosage
53(25.6%)
Phase 2Efficacy & side effects
124(59.9%)
Phase 3Large-scale testing
21(10.1%)
Phase 4Post-market surveillance
6(2.9%)
N/ANon-phased studies
2(1.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

78.0%

145 of 186 finished

Non-Completion Rate

22.0%

41 ended early

Currently Active

7

trials recruiting

Total Trials

208

all time

Status Distribution
Active(8)
Completed(145)
Terminated(41)
Other(14)

Detailed Status

Completed145
Terminated36
unknown13
Withdrawn5
Active, not recruiting5
Recruiting2

Development Timeline

Analytics

Development Status

Total Trials
208
Active
7
Success Rate
80.1%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (0.5%)
Phase 153 (25.6%)
Phase 2124 (59.9%)
Phase 321 (10.1%)
Phase 46 (2.9%)
N/A2 (1.0%)

Trials by Status

suspended10%
not_yet_recruiting10%
terminated3617%
completed14570%
unknown136%
withdrawn52%
recruiting21%
active_not_recruiting52%

Recent Activity

7 active trials
Showing 5 of 208
active_not_recruitingphase_3

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

NCT03007147
active_not_recruitingphase_2

Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia

NCT00070499
active_not_recruitingphase_4

Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator

NCT01742299
completedphase_2

PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study

NCT04129931
active_not_recruitingphase_2

I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

NCT04488081
View all 208 trials

Clinical Trials (208)

Showing 20 of 208 trialsScroll for more
NCT03007147Phase 3

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Active Not Recruiting
NCT00070499Phase 2

Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia

Active Not Recruiting
NCT01742299Phase 4

Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator

Active Not Recruiting
NCT04129931Phase 2

PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study

Completed
NCT04488081Phase 2

I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

Active Not Recruiting
NCT03516279Phase 2

Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

Active Not Recruiting
NCT06655246Phase 1

A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)

Recruiting
NCT03997903Phase 1

Imatinib for Pain in Sickle Cell Anemia

Terminated
NCT05623774Phase 1

A Dose Calibration Study Comparing IkT-001Pro to Imatinib Mesylate 400mg

Completed
NCT00015847Phase 2

Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia

Terminated
NCT05385549Phase 2

5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk

Recruiting
NCT01751425Phase 1

Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors

Terminated
NCT01085617

Standard Chemotherapy with or Without Nelarabine or Rituximab in Treating Patients with Newly Diagnosed Acute Lymphoblastic Leukemia

Completed
NCT00483366Phase 1

Imatinib Mesylate, Gemcitabine, and Capecitabine in Treating Patients With Advanced Solid Tumors

Completed
NCT01738139Phase 1

Ipilimumab and Imatinib Mesylate in Advanced Cancer

Completed
NCT04006769Early Phase 1

Entacapone Combination With Imatinib for Treatment of GIST

Completed
NCT04416750Phase 2

Positioning Imatinib for Pulmonary Arterial Hypertension

Unknown
NCT00928525Phase 2

Imatinib in Patients With Desmoid Tumor and Chondrosarcoma

Completed
NCT00161213Phase 2

Gemcitabine and Imatinib Mesylate as First-Line Therapy in Patients With Locally Adv. or Metastatic Pancreatic Cancer

Completed
NCT05970900Phase 3

Preoperative Imatinib Mesylate Combined With Rectal-sparing Surgery in Patients With c-KIT Gene-mutant Rectal GIST

Not Yet Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
208